Registered title, quoted from ClinicalTrials.gov
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Liaoning Cancer Hospital & Institute; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05132985, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically documented lung adenocarcinoma with completely resectable disease (Stage II-IIIB N2, according to the 8th edition of the IASLC Staging Manual in Thoracic Oncology)
Inclusion criterion 3
T4 tumors infiltrating the aorta, esophagus and/or heart
Exclusion criterion 4
ECOG PS 0/1 at enrollment, with no deterioration over the previous 2 weeks prior to baseline or day of first dosing
Inclusion criterion 6
A tumor which harbors either Ex19del or L858R EGFR-TKI-sensitizing mutations, either alone
Inclusion criterion 5
Hemoglobin: ≥9.0 g/dL
Inclusion criterion 8
Absolute neutrophil count: ≥1.5 × 109/l
Inclusion criterion 9
Platelet count: ≥100 × 109/l
Inclusion criterion 10
Serum bilirubin: ≤1.5 ULN
Inclusion criterion 11
ALT and AST: ≤2.5 × ULN
Inclusion criterion 12
Creatinine clearance: ≥60 ml/min
Inclusion criterion 13
EGFR-TKI-sensitizing mutations with T790M
Exclusion criterion 2
Mixed small cell and non-small-cell lung cancer histology
Exclusion criterion 3
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05132985, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Key Inclusion Criteria:
- Written informed consent
- Male or female, aged ≥18 years and ≤75 years
- Histologically or cytologically documented lung adenocarcinoma with completely resectable disease (Stage II-IIIB N2, according to the 8th edition of the IASLC Staging Manual in Thoracic Oncology)
- Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by an MDT evaluation
- A tumor which harbors either Ex19del or L858R EGFR-TKI-sensitizing mutations, either alone
- ECOG PS 0/1 at enrollment, with no deterioration over the previous 2 weeks prior to baseline or day of first dosing
- Adequate organ and marrow function as defined by:
- Hemoglobin: ≥9.0 g/dL
- Absolute neutrophil count: ≥1.5 × 109/l
- Platelet count: ≥100 × 109/l
- Serum bilirubin: ≤1.5 ULN
- ALT and AST: ≤2.5 × ULN
- Creatinine clearance: ≥60 ml/min
- Life expectancy of 6 months prior to randomization
Exclusion Criteria:
- Prior treatment with systemic anti-cancer treatment for NSCLC, EGFR-TKI treatment or pre-operative radiotherapy
- EGFR-TKI-sensitizing mutations with T790M
- Mixed small cell and non-small-cell lung cancer histology
- T4 tumors infiltrating the aorta, esophagus and/or heart
- Bulky N2 disease
- Candidates for segmentectomies or wedge resections only
- Medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment or any evidence of clinically active ILD
- Severe or uncontrolled systemic diseases/active infections, history of allogeneic organ transplantation, history of primary immunodeficiency, history of another primary malignancy
Quoted from ClinicalTrials.gov, NCT05132985, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05132985, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.